Organophosphorus pesticides (OPPs) are widely used and have recently been linked to metabolic syndrome (MS). This study aimed to investigate the probable association between chronic OPP exposure and MS among farm workers in Sharkia Governorate, Egypt, and to assess the potential role of peroxisome proliferator-activated receptor gamma (PPARγ). This comparative cross-sectional study included 140 participants, equally divided into OPP-exposed farm workers and non-exposed subjects. OPP exposure was confirmed by detecting plasma residues and cholinesterase activity. MS was diagnosed by assessing body mass index (BMI), waist circumference (WC), blood pressure, plasma glucose, serum insulin, and lipid parameters. Oxidative and inflammatory markers, including malondialdehyde (MDA), gamma-glutamyl transferase (GGT), ferritin, superoxide dismutase (SOD), tumor necrosis factor-alpha (TNF-α), and high-sensitivity C-reactive protein (hs-CRP), were measured. The mRNA expression of the PPARγ and paraoxonase 1 (PON1) genes was also investigated. In total, 60% of farm workers demonstrated MS, compared with 10% of non-exposed participants. Workers exhibited elevated oxidative and inflammatory indices and reduced PPARγ and PON1 expression. PPARγ positively correlated with high-density lipoprotein (HDL), SOD, and PON1, while negatively correlating with glucose, insulin resistance (IR), low-density lipoprotein (LDL), triglycerides (TGs), MDA, GGT, ferritin, TNF-α, and hs-CRP. The study concluded that chronic OPP exposure was associated with increased oxidative stress and inflammation, reduced PPARγ and PON1 expression, disturbed glucose and lipid metabolism, and increased IR. The observed associations between PPARγ downregulation, metabolic disturbances, and oxidative and inflammatory markers suggest that PPARγ dysregulation may represent a potential mechanistic link between chronic OPP exposure and MS. However, this proposed mechanism requires further validation.
International Journal of Life Science and Pharma Research
Both obesity and type 2 diabetes mellitus (T2DM) are independently associated with reduced serum testosterone. The additive effect of obesity and T2DM on reducing testosterone levels need to be investigated. Their combined additive effects may place obese T2DM patients at higher risk of decreased testosterone and the associated increased morbidity and mortality. The aim of this study was to screen obese T2DM patients for biochemical hypogonadism regardless of the presence of overt clinical symptoms to consider testosterone replacement therapy. 152 adult male aged 40 to 68 years with T2DM were recruited through simple random sampling. The study participants were grouped based on their BMI into lean (n=48); overweight (n=57), obese (n=37) and morbidly obese (n=11). Total serum testosterone (TST), BMI and waist circumference (WC) were measured in all patients and luteinizing hormone (LH) was measured in 103 of them. Low TST was defined as TST<9nmol/L and the normal range for LH was 1.7-11.2mIU/ml. Mean TST in lean T2DM patients was 15.61± 6.0 nmol/l. TST levels were significantly lower in obese and morbidly obese groups compared with the lean group (P=0.003 and 0.015 respectively). TST negatively correlated with BMI (r= -0.29, P<0.001) and WC (r= -0.21, P<0.009). Overall, 19.7% of T2DM patients had low TST. The prevalence of low TST increased from 14.9% in lean, to 21.1% in overweight, to 21.6% in obese, to 27.3% in morbidly obese T2DM patients, (P=0.74). LH was inappropriately normal in 95% (19/20) of patients with low TST. Obese T2DM patients had reduced TST levels and a higher prevalence of reduced TST compared to lean patients. TST negatively correlated with BMI and WC. Therefore, screening obese T2DM patients for testosterone deficiency should be considered.
type 2 diabetesobesitymorbid obesityandrogen deficiency
Saudi Journal of Biological Sciences · مجلد 28 (8) · 4183-4190
Diabetes Mellitus (DM) is one of the important public health issues worldwide. The Fat mass obesity (FTO) gene rs-9939609 variant identified single nucleotide polymorphism (SNP) with the T to A missense mutation, and has a strong association with T2DM. FTO gene is present on chromosome “16q12.2” comprising of nine exons. FTO gene rs-9939609 a variant is commonly found in the Pakistani Population. The purpose of the study was to alert the population about the rs-9939609 variant SNP, having a strong association with T2DM. Total of 190 participants were included in the present cross-sectional study. To collect the samples non-probability convenience technique was used. subjects were recruited and divided into three groups, normal healthy subjects, obese and T2DM. The patients were selected from the Medicine department Jamshoro/Hyderabad by filling the pre-designed proforma, as well as verbal and written consent taken from study participants. To analysed the data ANOVA Post hoc (Tukey-test) was applied for comparison among groups (P < 0.05) and “SNP-STAT” online software was used for frequencies. The BMI, neck circumference, waist circumference and lipid profile, fasting blood sugar and HbA1c was found significant (p < 0.001) in both genders as compared to control. Homozygous and heterozygous distribution of allelic and genotyping frequency was found in study participants. 37.9 %T/A, 57.4% T/T, and A/A were 4.7%. The FTO gene rs-9939609 variant amplified and have an increased risk of developing T2DM in the Sindh population. Codominant model odd ratio of T/A showed 2.42 (CI)1.23–3.84, with significant p < 0.032. The present study concluded that the FTO gene SNP rs-9939609 variant was found in the population of Hyderabad, Sindh and having strong association with T2DM and obese individuals. Increase BMI, neck and waist circumference are the biomarkers of obesity and causative factors of T2DM.
International Journal of Life Science and Pharma Research
Both obesity and type 2 diabetes mellitus (T2DM) are independently associated with reduced serum testosterone. The additive effect of obesity and T2DM on reducing testosterone levels need to be investigated. Their combined additive effects may place obese T2DM patients at higher risk of decreased testosterone and the associated increased morbidity and mortality. The aim of this study was to screen obese T2DM patients for biochemical hypogonadism regardless of the presence of overt clinical symptoms to consider testosterone replacement therapy. 152 adult male aged 40 to 68 years with T2DM were recruited through simple random sampling. The study participants were grouped based on their BMI into lean (n=48); overweight (n=57), obese (n=37) and morbidly obese (n=11). Total serum testosterone (TST), BMI and waist circumference (WC) were measured in all patients and luteinizing hormone (LH) was measured in 103 of them. Low TST was defined as TST<9nmol/L and the normal range for LH was 1.7-11.2mIU/ml. Mean TST in lean T2DM patients was 15.61± 6.0 nmol/l. TST levels were significantly lower in obese and morbidly obese groups compared with the lean group (P=0.003 and 0.015 respectively). TST negatively correlated with BMI (r= -0.29, P<0.001) and WC (r= -0.21, P<0.009). Overall, 19.7% of T2DM patients had low TST. The prevalence of low TST increased from 14.9% in lean, to 21.1% in overweight, to 21.6% in obese, to 27.3% in morbidly obese T2DM patients, (P=0.74). LH was inappropriately normal in 95% (19/20) of patients with low TST. Obese T2DM patients had reduced TST levels and a higher prevalence of reduced TST compared to lean patients. TST negatively correlated with BMI and WC. Therefore, screening obese T2DM patients for testosterone deficiency should be considered.
type 2 diabetesobesityhypogonadismandrogen deficiency